Bone morphogenetic protein 4 thermosensitive hydrogel inhibits corneal neovascularization by repairing corneal epithelial apical junctional complexes

Nan, Weijin; Shen, Sitong; Yang, Yongyan; Wu, Meiliang; He, Yuxi; Zhang, Ruiting; Cui, Xuejun; Zhang, Yan

doi:10.1016/j.mtbio.2024.100944

Materials Today Bio

2024

DOI: 10.1016/j.mtbio.2024.100944

|View full text |Cite

Bone morphogenetic protein 4 thermosensitive hydrogel inhibits corneal neovascularization by repairing corneal epithelial apical junctional complexes

Weijin Nan,

Sitong Shen,

Yongyan Yang

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Advancements in hydrogel technology for ocular drug delivery

Truong,

Wu,

Nguyen

et al. 2024

Explor BioMat-X

View full text Add to dashboard Cite

Hydrogel-based drug delivery systems (DDS) offer promising alternatives for treating ocular diseases by overcoming the limitations of traditional therapies, such as low bioavailability, frequent administration, and invasiveness. Hydrogels, with their high biocompatibility and ability to respond to external stimuli, can provide sustained and targeted drug delivery. This review highlights the unique properties of hydrogels, including their swelling behavior, porosity, and mechanical strength, making them suitable for various ocular applications. The classification of hydrogels based on cross-linking methods, origins, and stimuli responsiveness is discussed, emphasizing their potential in drug delivery for dry eye disease (DED), glaucoma, corneal alkali burns, and neovascularization. Notable advances include thermosensitive and pH-responsive hydrogels, which have shown promising results in preclinical studies. Despite these advances, most studies are still in preclinical stages, highlighting the need for rigorous human trials to validate the safety and efficacy of hydrogel DDS. Collaborative efforts among researchers, pharmacologists, and ophthalmologists are essential to translating these innovations into clinical practice, ultimately improving patient outcomes in ocular disease management.

show abstract

Advancements in hydrogel technology for ocular drug delivery

Truong,

Wu,

Nguyen

et al. 2024

Explor BioMat-X

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Bone morphogenetic protein 4 thermosensitive hydrogel inhibits corneal neovascularization by repairing corneal epithelial apical junctional complexes

Cited by 1 publication

References 47 publications

Advancements in hydrogel technology for ocular drug delivery

Advancements in hydrogel technology for ocular drug delivery

Contact Info

Product

Resources

About